Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice

Over the past few decades, the clinical outcomes of patients with cancer have significantly improved mostly owing to the development of effective chemotherapeutic treatments. However, chronic health conditions such as bone mass loss and risk of fragility fractures caused by chemotherapy have also em...

Full description

Bibliographic Details

Published in:	Bone Reports
Main Authors:	Takahiro Ishizaka, Keisuke Horiuchi, Shinya Kondo, Masashi Isaji, Takahiro Nakagawa, Masahiro Inoue, Hajime Rikitake, Eiko Taguchi, Michiro Susa, Masaki Yoda, Takeshi Ono, Yusuke Kozai, Kazuhiro Chiba
Format:	Article
Language:	English
Published:	Elsevier 2023-06-01
Subjects:	Cancer treatment-induced bone loss Eribulin mesylate Osteoclast Bisphosphonate RANKL Osteoprotegerin
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352187223000414